(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. READ MORE…
The post Niraparib Approved for Maintenance Treatment of Ovarian Cancer appeared first on Ovarian Cancer Research Fund Alliance.
(March 23, 2017) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 11-14, 2017 in Maryland. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA… More
(March 15, 2017) Results from a large study showed that screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the year after screening ended. However, it is not yet known whether this screening approach would improve survival in screened high-risk women. The results of the study… More
The post Screening High-Risk Women Catches More Early Stage Ovarian Cancers appeared first on Ovarian Cancer Research Fund Alliance.
News and Events
The next Upstate Dragon Boat Festival date is May 6, 2017 Read More